Lexaria Bioscience Initiates Studies Investigating DehydraTECHTM-CBD as a Potential Therapeutic for Dementia and Diabetes
Drug delivery innovator, Lexaria Bioscience (NASDAQ: LEXX) believes its proprietary drug delivery technology, DehydraTECH processed with cannabidiol (CBD) may have applications in the treatment of dementia and diabetes.
Lexaria has previously demonstrated the safety and efficacy of DehydraTECH-CBD in human hypertension studies, and has initiated two new studies to investigate the effect of the compound on two of the world’s largest public health concerns.
The global dementia drug market is projected to reach $32.3 billion by 2030 diabetes and the diabetes drug market is expected to reach $82.92 billion by 2027.
- Lexaria’s dementia study (DEM-A22-1) is a dose-ranging, two-month program in 32 Long Evans rats to investigate whether CBD enables cognitive performance enhancements and could potentially be of utility in dementia treatment.
- The company’s diabetes study (DIAB-A22-1) is a dose-ranging, 56-day program in 32 Zucker rats that will compare weight gain, blood glucose, cholesterol and trigyceride levels in animals that receive DehydraTECH-CBD to those that do not.
- Dementia is currently the seventh leading cause of death among all diseases.
- By 2045, it is estimated that over 700 million people worldwide will be living with diabetes.
Lexaria’s studies in dementia and diabetes will be undertaken by a leading, third-party testing laboratory located in Canada. The laboratory work is expected to be complete in late January 2023.